← Theranostic Atlas Therapy radar Imaging radar All targets Molecules Français Molecules
Florbetapir Target Amyloid Class Small molecule (stilbene) Other names AV-45
1 ongoing trials
1 radiolabelled forms
1 approved products
1,089 publications (PubMed)
Structure 3D 2D
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: PubChem (3D conformer computed by PubChem). Rotate with the mouse or a finger.
Properties (PubChem) Molecular formula C20H25FN2O3 Molar mass (g/mol) 359.4 Exact mass (Da) 359.1875 XLogP 3.5 H-bond donors 1 H-bond acceptors 6 Rotatable bonds 12 Heavy atoms 26 InChIKey YNDIAUKFXKEXSV-CRYLGTRXSA-N PubChem record CID 24822371 ↗ IUPAC name 4-[(E)-2-[6-[2-[2-(2-(18F)fluoroethoxy)ethoxy]ethoxy]-3-pyridinyl]ethenyl]-N-methyl(18F)aniline SMILES CNC1=CC=C(C=C1)/C=C/C2=CN=C(C=C2)OCCOCCOCC[18F] Radiolabelled forms Form Use Molar mass (labelled form) Ongoing trials Most advanced phase Approval [¹⁸F]florbetapir Imaging 359.4 1 Phase 3 Amyvid, Vizamyl, Neuraceq US EU FR JP
Atlas trials whose studied drug or title names this vector, with this radionuclide.
Trial Phase Status Sponsor Countries Amyloid tracers NCT07012993 · Alzheimer's disease and cognitive disorders Phase 2 Recruiting Akiva Mintz 1
Other trials listing it among the interventions (comparator, associated scan) · 5 Abeta-MTRALCA · Amyloid tracers NCT07829705 · Cardiac amyloidosis Phase 2 Recruiting Peking Union Medical College Hospital 1 Amyloid tracers NCT07787169 · Alzheimer's disease and cognitive disorders Phase 1 Recruiting Eli Lilly and Company 3 EPSMS · Amyloid tracers NCT04390009 · Neuroinflammation and multiple sclerosis Phase 1 Recruiting Brain Health Alliance 1 MICA · Amyloid tracers NCT02641145 · Cardiac amyloidosis No phase Recruiting Brigham and Women's Hospital 1 Amyloid tracers NCT01606488 · Alzheimer's disease and cognitive disorders No phase Active, not recruiting University of California, San Francisco 1
1,089 publications in PubMed for the query below; the most recent:
florbetapir[tiab]
APOE4 moderates the association of sleep disturbance with cerebral amyloid burden but not with clinical conversion in cognitively normal older adults J Alzheimers Dis, 2026 A Two-Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p-Tau217 Gray Zone Ann Clin Transl Neurol, 2026 Short-Duration [(18)F]florbetapir PET Reconstructions: Centiloid Agreement and Temporal-Window Analysis AJNR Am J Neuroradiol, 2026 Continuous amyloid staging complements global amyloid burden in early Alzheimer's disease bioRxiv, 2026 Greater amyloid burden in cognitive networks in preclinical Alzheimer's disease J Alzheimers Dis, 2026 Comparison of baseline characteristics between cognitively normal and mild cognitive impairment and association of white matter hyperintensity trajectories with diagnostic outcomes, cognition, and amyloid-β protein: A longitudinal study J Alzheimers Dis, 2026 Omega-3 fatty acids and Alzheimer's disease-related brain biomarkers in older adults enriched for preclinical Alzheimer's disease Prostaglandins Leukot Essent Fatty Acids, 2026 Multimodal Imaging of Tau Pathology and Network Connectivity Dynamics Across the Alzheimer's Continuum: A Pilot Study Using Second-Generation Tracer [(18)F]MK6240 Acad Radiol, 2026 Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
Cite this page Florbetapir. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/florbetapir/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.